Anterior chamber bleeding after laser peripheral iridotomy

Area of Science:

• Ophthalmology
• Glaucoma Research
• Surgical Complications

Background:

• Laser peripheral iridotomy (LPI) is a common procedure for primary angle-closure glaucoma (PACS).
• The use of antiplatelet and anticoagulant medications raises concerns about potential bleeding complications after LPI.
• Previous studies have not specifically evaluated the safety of continuing these medications during LPI.

Purpose of the Study:

• To determine the incidence and severity of anterior chamber bleeding after LPI in patients on antiplatelet/anticoagulant therapy compared to those who discontinued treatment.
• To assess the impact of continuing antiplatelet/anticoagulant therapy on intraocular pressure post-LPI.

Main Methods:

• A prospective controlled trial involving 104 patients with suspected bilateral PACS.
• Patients regularly taking antiplatelet or anticoagulant medications were divided into treatment and non-treatment arms for LPI.
• The primary outcome measured was the incidence and amount of anterior chamber bleeding.

Main Results:

• Bleeding occurred in 34.6% of eyes in both the treated and untreated groups.
• No significant difference in bleeding amount or immediate post-LPI intraocular pressure was observed between groups.
• Medication type, laser energy, age, sex, and iris color were not identified as risk factors for increased bleeding.

Conclusions:

• Discontinuing antiplatelet or anticoagulant therapy is not indicated before performing high-powered pulsed laser peripheral iridotomy.
• Continuing these medications does not appear to increase the risk of anterior chamber bleeding or affect intraocular pressure after LPI.